Company profile: Rivus Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biopharmaceutical, oral small-molecule Controlled Metabolic Accelerators (CMAs) that activate mitochondrial uncoupling to reduce excess fat, increase energy expenditure, and preserve muscle mass for treating obesity and associated cardiometabolic diseases. Pipeline includes HU6, an investigational CMA, and RV-002, a preclinical ANT activator targeting obesity and cardiovascular disease.
Products and services
- Controlled Metabolic Accelerators (CMAs): Oral small-molecule products that activate mitochondrial uncoupling to increase energy expenditure, reduce excess fat, and preserve muscle mass in cardiometabolic disease contexts
- HU6: Investigational controlled metabolic accelerator leveraging mitochondrial uncoupling to reduce fat while preserving muscle mass, engineered to treat obesity and associated cardiometabolic diseases
- RV-002: Preclinical candidate targeting obesity and cardiovascular disease through activation of adenine nucleotide translocase (ANT), with a focus on ANT-driven mechanisms
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Rivus Pharmaceuticals
CorFlow Therapeutics
HQ: Switzerland
Website
- Description: Provider of proprietary medtech technologies to diagnose and treat microvascular obstructions (MVO) in heart attack patients. Offers the CoFI System for post-PCI coronary microcirculation assessment and controlled infusion of diagnostic/therapeutic agents, the CoFI Console acting as an infusion pump and displaying physiological parameters, an infusion-occlusion CoFI Catheter, and a single-use CoFI Cassette.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CorFlow Therapeutics company profile →
Vitatron
HQ: The Netherlands
Website
- Description: Provider of pacemakers—implanted devices that deliver timed electrical discharges to regulate slow or irregular heart rhythms—and the Vitatron 2090 Programmer, used to program and support advanced Vitatron cardiac devices to meet patient-specific needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vitatron company profile →
WorldHeart
HQ: United States
Website
- Description: Provider of the MiFlow VAD, a minimally-invasive, magnetically-levitated miniature rotary blood pump.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full WorldHeart company profile →
Tricares
HQ: France
Website
- Description: Provider of minimally invasive, catheter-based tricuspid valve replacement solutions for tricuspid valve regurgitation, featuring the Topaz Transfemoral Tricuspid Valve Replacement (TTVR) system for transfemoral native valve replacement, the self-expanding biological Topaz Heart Valve Prosthesis, and the Topaz Implantation System for steerable venous access and prosthesis delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tricares company profile →
Xeltis
HQ: The Netherlands
Website
- Description: Provider of polymer-based restorative cardiovascular devices, including implantable small-diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft surgery, and pulmonary heart valves. Products include aXess; XABG/Xabg; and Xplore-2, designed to transform into a living valve made of the patient’s own tissue, aiming to reduce reintervention rates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xeltis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Rivus Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Rivus Pharmaceuticals
2.2 - Growth funds investing in similar companies to Rivus Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Rivus Pharmaceuticals
4.2 - Public trading comparable groups for Rivus Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →